Gastric Cancer

Oncology
55
Pipeline Programs
30
Companies
50
Clinical Trials
12 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
10
9
12
3
17
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1043%
Small Molecule
835%
Cell Therapy
417%
ADC
14%
+ 39 programs with unclassified modality

On Market (3)

Approved therapies currently available

Eli Lilly and Company
CYRAMZAApproved
ramucirumab
Eli Lilly and Company
Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]injection2014
Roche
HERCEPTINApproved
trastuzumab
Roche
HER2/neu Receptor Antagonist [EPC]intravenous1998
Bristol Myers Squibb
OPDIVOApproved
nivolumab
Bristol Myers Squibb
injection2015

Competitive Landscape

29 companies ranked by most advanced pipeline stage

Roche
RocheSTAVANGER NORWAY, Norway
9 programs
2
3
1
trastuzumab [Herceptin]Phase 41 trial
5-FluorouracilPhase 32 trials
TrastuzumabPhase 3Monoclonal Antibody
cisplatin+capecitabinePhase 31 trial
AtezolizumabPhase 2Monoclonal Antibody1 trial
+4 more programs
Active Trials
NCT01679054Completed58Est. Jul 2012
NCT02538562Completed1,695Est. Apr 2013
NCT02063412Withdrawn0Est. Apr 2014
+9 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
1
1
1
RamucirumabPhase 3Monoclonal Antibody1 trial
LY2875358Phase 21 trial
Active Trials
NCT01874938Completed15Est. Dec 2014
NCT01170663Completed665Est. Feb 2017
Bristol Myers Squibb
1 program
1
1
NivolumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT03006705Completed800Est. Mar 2023
Zai Lab
Zai LabCA - South SF
5 programs
1
1
1
1
BemarituzumabPhase 3Monoclonal Antibody
margetuximabPhase 2/3Monoclonal Antibody1 trial
BemarituzumabPhase 2Monoclonal Antibody1 trial
Niraparib combined with MGD013Phase 11 trial
NovoTTF-100LN/A1 trial
Active Trials
NCT04281576Completed28Est. Jun 2024
NCT04178460Terminated60Est. Mar 2022
NCT03694522Completed155Est. May 2022
+1 more trials
Pfizer
PfizerNEW YORK, NY
3 programs
1
1
IsovorinPhase 31 trial
Oxaliplatin, Irinotecan, Bevacizumab, DocetaxelPhase 2
Multimodal analgesiaN/A1 trial
Active Trials
NCT03236051Unknown156Est. Aug 2018
NCT00195572Completed200Est. Aug 2008
Taiho Oncology
Taiho OncologyNJ - Princeton
3 programs
1
2
S-1/CisplatinPhase 31 trial
continuous infusion of 5-fluorouracilPhase 31 trial
S-1Phase 1/21 trial
Active Trials
NCT00072787CompletedEst. May 2006
NCT00400179CompletedEst. Apr 2008
NCT00142350CompletedEst. Jan 2007
DS
Daiichi SankyoChina - Shanghai
3 programs
1
2
IrinotecanPhase 31 trial
Trastuzumab DeruxtecanPhase 3ADC1 trial
FluorouracilPhase 21 trial
Active Trials
NCT04379596Recruiting450Est. Jun 2027
NCT01813253Terminated400Est. Feb 2018
NCT06731478Recruiting726Est. Feb 2030
Elevar Therapeutics
Elevar TherapeuticsKorea - Seoul
2 programs
1
1
RivoceranibPhase 3Small Molecule1 trial
RivoceranibPhase 1/2Small Molecule1 trial
Active Trials
NCT03707028Terminated12Est. Aug 2021
NCT03042611Completed460Est. Sep 2020
Amgen
AmgenTHOUSAND OAKS, CA
2 programs
2
BemarituzumabPhase 3Monoclonal Antibody1 trial
RilotumumabPhase 3Monoclonal Antibody2 trials
Active Trials
NCT05111626Active Not Recruiting515Est. Jan 2027
NCT01791374Completed21Est. Mar 2015
NCT01697072Terminated609Est. Aug 2015
Genentech
GenentechCA - Oceanside
1 program
1
5-FluoruracilPhase 3
CP
Chugai PharmaJapan - Tokyo
1 program
1
TrastuzumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT01041404Completed584Est. Jun 2010
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
1
Ultrasonically activated ShearsPhase 31 trial
Active Trials
NCT01971775Completed56
CT
3 programs
1
1
1
AnlotinibPhase 2/3Small Molecule1 trial
AnlotinibPhase 2Small Molecule1 trial
Ramucirumab InjectionPhase 11 trial
Active Trials
NCT05800418CompletedEst. Feb 2020
NCT06222944Not Yet RecruitingEst. Aug 2026
NCT02461407UnknownEst. Dec 2017
ALX Oncology
ALX OncologyCA - South SF
1 program
1
EvorpaceptPhase 2/3
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
4 programs
1
2
1
AZD0901Phase 22 trials
AZD4360Phase 1/21 trial
AZD5863Phase 1/21 trial
VolitinibPhase 1Small Molecule
Active Trials
NCT06921928Recruiting117Est. Dec 2027
NCT06005493Recruiting280Est. Jul 2027
NCT07143604Recruiting33Est. Sep 2027
+1 more trials
H
HutchmedChina - Hong Kong
3 programs
1
1
1
SavolitinibPhase 2Small Molecule1 trial
fruquintinib+paclitaxelPhase 1/21 trial
VolitinibPhase 1Small Molecule1 trial
Active Trials
NCT02252913Completed25Est. Dec 2015
NCT02415023Completed34Est. Mar 2017
NCT04923932Active Not Recruiting75Est. Dec 2026
M&
Merck & Co.RAHWAY, NJ
1 program
1
ARQ 197Phase 21 trial
Active Trials
NCT01070290Withdrawn0
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
Cisplatin-5FU-AfatinibPhase 2Small Molecule1 trial
Active Trials
NCT01743365Completed55Est. Jul 2019
Novartis
NovartisBASEL, Switzerland
1 program
1
Irinotecan associated to fluorouracil and leucovorinPhase 2
Precision BioSciences
4 programs
2
2
CEA-targeted CAR-T cellsPhase 1/2Cell Therapy1 trial
CEA-targeted CAR-T cellsPhase 1/2Cell Therapy1 trial
CEA CAR-T cellsPhase 1Cell Therapy1 trial
CEA-targeted CAR-T cellsPhase 1Cell Therapy1 trial
Active Trials
NCT06010862Recruiting36Est. Sep 2026
NCT06126406Recruiting60Est. Dec 2026
NCT06006390Recruiting60Est. Aug 2026
+1 more trials
E
EisaiChina - Liaoning
1 program
1
E7070Phase 1/21 trial
Active Trials
NCT00165594Terminated50Est. Aug 2006
I
IdienceCA - San Francisco
1 program
1
IDX-1197+XELOXPhase 1/21 trial
Active Trials
NCT04725994RecruitingEst. Jun 2026
Curis
CurisMA - Lexington
1 program
1
CA-4948Phase 11 trial
Active Trials
NCT05187182RecruitingEst. Jun 2028
HiFiBiO Therapeutics
HiFiBiO TherapeuticsMA - Cambridge
1 program
1
HFB200301Phase 11 trial
Active Trials
NCT05238883Active Not RecruitingEst. Dec 2026
InxMed
InxMedChina - Beijing
1 program
1
IN10018Phase 11 trial
Active Trials
NCT05327231Completed33Est. Mar 2022
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
VeliparibPhase 15 trials
Active Trials
NCT03123211No Longer Available
NCT03044795Withdrawn0Est. Nov 2020
NCT02158507Completed20Est. Jul 2021
+2 more trials
Verona Pharma
Verona PharmaUK - London
3 programs
Avoid drain placementN/A1 trial
DaVinci® Surgical SystemN/A1 trial
pre- or perioperative treatment and D2 gastrectomyN/A1 trial
Active Trials
NCT04227951Completed404Est. Mar 2023
NCT06362070Recruiting75Est. Jul 2025
NCT06472063RecruitingEst. Sep 2024
Beacon Therapeutics
Beacon TherapeuticsMA - Cambridge
1 program
Bismuth-based quadruple therapyN/A1 trial
Active Trials
NCT06275204RecruitingEst. Dec 2026
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Laparoscopic gastrectomyN/A1 trial
Active Trials
NCT06202105RecruitingEst. Aug 2032

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Rochetrastuzumab [Herceptin]
Roche5-Fluorouracil
Daiichi SankyoTrastuzumab Deruxtecan
RocheCisplatin
AmgenBemarituzumab
Elevar TherapeuticsRivoceranib
Bristol Myers SquibbNivolumab
Roche5-Fluorouracil
Daiichi SankyoIrinotecan
AmgenRilotumumab
Johnson & JohnsonUltrasonically activated Shears
Eli Lilly and CompanyRamucirumab
Rochecisplatin+capecitabine
Chugai PharmaTrastuzumab
Taiho OncologyS-1/Cisplatin

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 9,222 patients across 50 trials

NCT01260194Rochetrastuzumab [Herceptin]

A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer

Start: Jun 2011Est. completion: Jan 20154 patients
Phase 4Terminated
NCT00000758Roche5-Fluorouracil

A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women

Est. completion: Apr 1998158 patients
Phase 3Completed
NCT06731478Daiichi SankyoTrastuzumab Deruxtecan

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Start: Feb 2025Est. completion: Feb 2030726 patients
Phase 3Recruiting
NCT06624059RocheCisplatin

A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)

Start: Nov 2024Est. completion: Mar 203311 patients
Phase 3Active Not Recruiting
NCT05111626AmgenBemarituzumab

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.

Start: Mar 2022Est. completion: Jan 2027515 patients
Phase 3Active Not Recruiting
NCT03042611Elevar TherapeuticsRivoceranib

A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer

Start: Mar 2017Est. completion: Sep 2020460 patients
Phase 3Completed
NCT03006705Bristol Myers SquibbNivolumab

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

Start: Jan 2017Est. completion: Mar 2023800 patients
Phase 3Completed
NCT01774786Roche5-Fluorouracil

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

Start: Jun 2013Est. completion: Dec 2019780 patients
Phase 3Completed
NCT01813253Daiichi SankyoIrinotecan

Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

Start: May 2013Est. completion: Feb 2018400 patients
Phase 3Terminated
NCT01697072AmgenRilotumumab

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Start: Oct 2012Est. completion: Aug 2015609 patients
Phase 3Terminated
NCT01971775Johnson & JohnsonUltrasonically activated Shears

Clinical Study for Energy Based Devices in Open Gastrectomy for Gastric Cancer

Start: Aug 201156 patients
Phase 3Completed
NCT01170663Eli Lilly and CompanyRamucirumab

A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma

Start: Dec 2010Est. completion: Feb 2017665 patients
Phase 3Completed
NCT00407186Rochecisplatin+capecitabine

Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)

Start: Jan 2007Est. completion: Dec 2025788 patients
Phase 3Unknown
NCT01041404Chugai PharmaTrastuzumab

ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer

Start: Sep 2005Est. completion: Jun 2010584 patients
Phase 3Completed
NCT00400179Taiho OncologyS-1/Cisplatin

A Safety and Efficacy Study in Patients With Gastric Cancer

Start: May 2005Est. completion: Apr 2008
Phase 3Completed
NCT00195572PfizerIsovorin

Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer

Start: May 2002Est. completion: Aug 2008200 patients
Phase 3Completed
NCT00142350Taiho Oncologycontinuous infusion of 5-fluorouracil

A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer

Start: Nov 2000Est. completion: Jan 2007
Phase 3Completed
NCT04082364Zai Labmargetuximab

Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Start: Sep 2019Est. completion: Mar 202582 patients
Phase 2/3Completed
NCT02461407Chia Tai TianQing Pharmaceutical GroupAnlotinib

Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)

Start: Jun 2015Est. completion: Dec 2017
Phase 2/3Unknown
NCT01070290Merck & Co.ARQ 197

A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen

0
Phase 2Withdrawn
NCT07143604AstraZenecaAZD0901

A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2

Start: Aug 2025Est. completion: Sep 202733 patients
Phase 2Recruiting
NCT06222944Chia Tai TianQing Pharmaceutical GroupAnlotinib

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Start: Feb 2024Est. completion: Aug 2026
Phase 2Not Yet Recruiting
NCT06219941AstraZenecaAZD0901

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Start: Dec 2023Est. completion: Sep 2027224 patients
Phase 2Recruiting
NCT04923932HutchmedSavolitinib

Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

Start: Jul 2021Est. completion: Dec 202675 patients
Phase 2Active Not Recruiting
NCT04661150RocheAtezolizumab

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

Start: Mar 2021Est. completion: Jul 202642 patients
Phase 2Active Not Recruiting
NCT04379596Daiichi SankyoFluorouracil

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

Start: Jun 2020Est. completion: Jun 2027450 patients
Phase 2Recruiting
NCT03044795AbbVieVeliparib

Response to PARP Inhibitor Predicted by the RAD51 Assay

Start: Nov 2019Est. completion: Nov 20200
Phase 2Withdrawn
NCT03694522Zai LabBemarituzumab

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer

Start: Sep 2018Est. completion: May 2022155 patients
Phase 2Completed
NCT01874938Eli Lilly and CompanyLY2875358

A Study of LY2875358 in Participants With MET Positive, Advanced Gastric Cancer

Start: Aug 2013Est. completion: Dec 201415 patients
Phase 2Completed
NCT01743365Boehringer IngelheimCisplatin-5FU-Afatinib

Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer

Start: Feb 2013Est. completion: Jul 201955 patients
Phase 2Completed
NCT01461057RocheCisplatin

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer

Start: Dec 2011Est. completion: Oct 201730 patients
Phase 2Completed
NCT00454636RocheCisplatin

A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.

Start: Mar 2007Est. completion: Jul 2010158 patients
Phase 2Completed
NCT06921928AstraZenecaAZD4360

Study for AZD4360 in Participants With Advanced Solid Tumours

Start: Apr 2025Est. completion: Dec 2027117 patients
Phase 1/2Recruiting
NCT06006390Precision BioSciencesCEA-targeted CAR-T cells

CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors

Start: Sep 2023Est. completion: Aug 202660 patients
Phase 1/2Recruiting
NCT06005493AstraZenecaAZD5863

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Start: Jul 2023Est. completion: Jul 2027280 patients
Phase 1/2Recruiting
NCT05789082RocheCisplatin

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Start: Jun 2023Est. completion: Jan 2032320 patients
Phase 1/2Recruiting
NCT05538195Precision BioSciencesCEA-targeted CAR-T cells

Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors

Start: Jun 2022Est. completion: Jun 202560 patients
Phase 1/2Unknown
NCT04725994IdienceIDX-1197+XELOX

Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer

Start: Jun 2021Est. completion: Jun 2026
Phase 1/2Recruiting
NCT03707028Elevar TherapeuticsRivoceranib

A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

Start: Oct 2018Est. completion: Aug 202112 patients
Phase 1/2Terminated
NCT02415023Hutchmedfruquintinib+paclitaxel

A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer

Start: Nov 2014Est. completion: Mar 201734 patients
Phase 1/2Completed
NCT00165594EisaiE7070

A Study of E7070 in Patients With Gastric Cancer

Start: Feb 2005Est. completion: Aug 200650 patients
Phase 1/2Terminated
NCT00072787Taiho OncologyS-1

Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer

Start: Oct 2003Est. completion: May 2006
Phase 1/2Completed
NCT06126406Precision BioSciencesCEA-targeted CAR-T cells

Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors

Start: Nov 2023Est. completion: Dec 202660 patients
Phase 1Recruiting
NCT06010862Precision BioSciencesCEA CAR-T cells

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors

Start: Sep 2023Est. completion: Sep 202636 patients
Phase 1Recruiting
NCT05187182CurisCA-4948

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Start: Jun 2023Est. completion: Jun 2028
Phase 1Recruiting
NCT05238883HiFiBiO TherapeuticsHFB200301

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Start: Mar 2022Est. completion: Dec 2026
Phase 1Active Not Recruiting
NCT05327231InxMedIN10018

IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma

Start: Jul 2020Est. completion: Mar 202233 patients
Phase 1Completed
NCT04178460Zai LabNiraparib combined with MGD013

A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment

Start: Feb 2020Est. completion: Mar 202260 patients
Phase 1Terminated
NCT05800418Chia Tai TianQing Pharmaceutical GroupRamucirumab Injection

Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers

Start: Nov 2019Est. completion: Feb 2020
Phase 1Completed
NCT02252913HutchmedVolitinib

A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer

Start: Sep 2014Est. completion: Dec 201525 patients
Phase 1Completed

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
1h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
3h ago

Executive Director, I.T.- Head of Security Architecture, Engineering, and Delivery

Gilead Sciences
United States - California - Foster City
17h ago
$281K - $364K/yr

Sr Research Associate, Analytical Operations

Gilead Sciences
United States - California - Oceanside
17h ago
$86K - $112K/yr

Associate Director, Insights & Analytics Platform Technology Lead

Gilead Sciences
United States - California - Foster City
17h ago
$196K - $253K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

17 late-stage (Phase 3) programs — potential near-term approvals
12 actively recruiting trials targeting 9,222 patients
30 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)